Related Experiment Video
Updated: Mar 27, 2026

Comet Assay as an Indirect Measure of Systemic Oxidative Stress
Published on: May 22, 2015
The comet assay as a tool in human biomonitoring exposure to antineoplastic drugs - A systematic review and
Carina Ladeira1, Amaya Azqueta2, Lisa Giovannelli3
1ESSL-Escola Superior de Saúde, Instituto Politécnico de Lisboa, Lisbon, Portugal; Comprehensive Health Research Centre (CHRC), National School of Public Health, NOVA University of Lisbon, Lisboa, Portugal.
Abstract:
Antineoplastic agents are toxic compounds, generally used in the treatment of cancers, which are recognized as carrying a cancer development risk. In this systematic review and meta-analysis of human biomonitoring studies, we have assessed the effects of exposure to antineoplastic drugs on levels of DNA strand breaks in leukocytes, measured by the comet assay. Focusing on the application of the comet assay in human biomonitoring of occupational exposure to antineoplastic agents, we have analyzed 458 original research studies which used this assay, following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA-ScR). The systematic review led to 23 studies, of which 20 studies met the criteria for inclusion in the meta-analysis. Using standardized mean difference and 95% confidence interval (CI), the meta-analyses show increased levels of DNA strand breaks in subjects exposed to antineoplastic drugs (1.26, 95% CI: 0.78, 1.73). Results originate mainly from studies on healthcare workers, with only one study in an industrial setting. Subgroup analysis indicates that all studies combined from middle-income countries have a higher effect size (1.77, 95% CI: 1.00, 2.55) than studies from high-income countries (0.49, 95% CI: 0.09, 0.90). This difference between middle- and high-income countries may be attributable in part to differences in exposure levels or exposure assessment. Additionally, sensitivity analysis indicates that studies with moderate/high risk of comet assay measurement bias have higher effect size (2.07, 95% CI: 0.82, 3.31) than studies with low risk of bias (0.73, 95% CI: 0.34, 1.13); and that studies with high risk of exposure misclassification have higher effect size (1.47, 95% CI: 0.89, 2.06) than studies with low/moderate risk (0.13, 955 CI: -0.08, 0.33). Most studies have low/moderate risk of bias related to the comet assay procedure (15 out of 20 studies), absence of reporting the use of assay controls (1 out of 20 studies), blinded analysis of samples (7 out 20 studies); exposure assessment (16 out of 20 studies). In conclusion, this systematic review and meta-analysis shows that exposure to antineoplastic drugs is associated with increased levels of DNA strand breaks in human leukocytes.
Insights
Occupational exposure to antineoplastic drugs, used in cancer treatment, increases DNA strand breaks in leukocytes. This systematic review highlights the cancer development risk associated with these toxic compounds.
Area of Science:
- Biomonitoring
- Genotoxicology
- Occupational Health
Background:
- Antineoplastic agents, vital for cancer treatment, are recognized for their inherent toxicity and potential cancer development risk.
- Human biomonitoring studies are crucial for assessing occupational exposure risks to hazardous substances.
Purpose of the Study:
- To systematically review and meta-analyze human biomonitoring studies assessing the effects of antineoplastic drug exposure on DNA strand breaks in leukocytes.
- To evaluate the utility of the comet assay in human biomonitoring of occupational exposure to antineoplastic agents.
Main Methods:
- A systematic review and meta-analysis of 458 original research studies using the comet assay, adhering to PRISMA-ScR guidelines.
- Inclusion criteria led to 23 studies for the review and 20 for the meta-analysis.
- Standardized mean difference and 95% confidence intervals were used to analyze DNA strand break levels.
Main Results:
- Meta-analyses revealed significantly increased levels of DNA strand breaks in leukocytes of subjects exposed to antineoplastic drugs (SMD = 1.26, 95% CI: 0.78, 1.73).
- Studies from middle-income countries exhibited a higher effect size (1.77) compared to high-income countries (0.49).
- Higher effect sizes were observed in studies with moderate/high risk of comet assay measurement bias (2.07) and high risk of exposure misclassification (1.47).
Conclusions:
- Occupational exposure to antineoplastic drugs is associated with increased DNA strand breaks in human leukocytes.
- The findings underscore the genotoxic risk posed by antineoplastic agents, particularly in healthcare settings.
- Variations in effect size across countries and study biases highlight the need for standardized exposure assessment and assay methodology.

